Inflammation is likely a key player in atherosclerosis and related cardiovascular events, but questions remain about its role ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it ...

and reduce the inflammation biomarker high-sensitivity C-reactive protein in high-risk patients with high LDL cholesterol levels when statins are not working. Data from ODYSSEY OUTCOMES have also ...

Background: Statins that lower low-density lipoprotein (LDL ... After an average of four years, they found a statistically significant reduction in high-sensitivity CRP level by 0.34 mg/L in the ...

Cardiologists have known for more than three decades that statin-type cholesterol-lowering drugs can lower levels of ubiquinone. Most people know ubiquinone by the name coenzyme Q10 or CoQ10.

Cholesterol-lowering statin drugs could be available to millions more patients in the UK, if new recommendations from health technology assessment (HTA) organisation NICE are implemented.

Veru Inc. MIAMI, May 01, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of ...

When someone has a heart attack, doctors usually start treatment with high-intensity statins right away. These drugs lower "bad" LDL cholesterol, which can stabilize blood vessels and help prevent ...

Many times people die due to increased bad cholesterol. For this, everyone should do a high-sensitivity C-reactive protein test. If someone's heart history is related to heart, then its effect is ...

Background: Differences exist between European and American guideline recommendations regarding targets for low-density ...